MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
248.68
+1.17
+0.47%
After Hours: 250.00 +1.32 +0.53% 19:30 09/11 EDT
OPEN
248.05
PREV CLOSE
247.51
HIGH
254.08
LOW
246.01
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
197.81
MARKET CAP
33.28B
P/E (TTM)
42.32
1D
5D
1M
3M
1Y
5Y
1D
If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today
Benzinga · 1d ago
TCAF, CNP, COR, ALNY: ETF Inflow Alert
NASDAQ · 2d ago
Alnylam Pharmaceuticals Is Maintained at Hold by Jefferies
Dow Jones · 4d ago
Alnylam Pharmaceuticals Price Target Raised to $260.00/Share From $230.00 by Jefferies
Dow Jones · 4d ago
Alnylam price target raised to $260 from $230 at Jefferies
TipRanks · 4d ago
Weekly Report: what happened at ALNY last week (0831-0904)?
Weekly Report · 5d ago
Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data
Simply Wall St · 6d ago
Sandisk leads Nasdaq's weekly gainers; Autodesk drags
Seeking Alpha · 09/04 20:19
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.